- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Promise of Merck's Pembrolizumab in PD-L1-expressing NSCLC
Pembrolizumab was safe and effective in patients with locally advanced or metastatic non—small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.
Edward B. Garon, MD, assistant clinical professor and director of the thoracic oncology program at the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues sought to evaluate pembrolizumab (Merck) — previously known as lambrolizumab and MK-3475 — among patients with previously treated advanced NSCLC.
HemOnc Today
“We presented the initial data from lung cancer patients at the World Conference on Lung Cancer in Sydney last fall,” Garon told . “The question at that time was whether the impressive efficacy and tolerable safety profile could be confirmed in a larger population. We have now demonstrated similar results in over 200 additional patients.”
The analysis included 217 patients who were tested for PD-L1 expression using immunohistochemistry (IHC).
Read the report here: http://bit.ly/1kn49ov
Source: Healio
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
